AEON Biopharma, Inc. (AEON)
After hours:
| Previous Close | 4.25 |
| Open | 4.13 |
| Bid | 4.82 x 900 |
| Ask | 6.00 x 1100 |
| Day's Range | 4.13 - 5.07 |
| 52 Week Range | 3.37 - 17.17 |
| Volume | |
| Avg. Volume | 65,534 |
| Market Cap | 193.27M |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksHere's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for AEON Biopharma, Inc. (AEON), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
GlobeNewswireCORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first paragraph it incorrectly referenced March 29, 2024 as the Redemption Date. The Redemption Date is April 29, 2024. March 29, 2024 is the date on which the notice of redemption was delivered to warrant holders. The corrected release follows: AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Comp
- GlobeNewswire
AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), that
